AstraZeneca on Tuesday said that it had begun a clinical trial of a drug designed to both prevent infection and treat people with COVID-19, with the first volunteers receiving doses.

AstraZeneca on Tuesday said that it had begun a clinical trial of a drug designed to both prevent infection and treat people with COVID-19, with the first volunteers receiving doses. Also read: Second wave of Covid-19? Re-infections in Belgium and the Netherlands make experts wary According to the pharma giant, the drug, known as AZD7442, is a combination of two antibodies and is being tested on 48 healthy people aged between 18 and 55. "This trial is an important milestone in the development of our monoclonal antibody combination to prevent or treat COVID-19," said Mene Pangalos, executive vice-president of biopharmaceuticals research and development at AstraZeneca. Also read: Pandemic pace slows worldwide except for Southeast Asia, Eastern Mediterranean: WHO The pharmaceuticals company said that such trials would help evaluate the safety of the drug and be used both to prevent the disease and to stop it from progressing in patients already infected. Results from the trial are expected by the end of this year. This latest trial involving AstraZeneca comes in addition to its partnership with the University of Oxford on the development of a separate coronavirus vaccine, which is said to have produced promising results. News of the latest trial helped shares in AstraZeneca to rise in early trading on Tuesday. (Inputs from agencies)

AstraZeneca conducts clinical trials of COVID-19 drug

AstraZeneca Plc on Thursday signed a deal with a China-based company for producing its potential drug to treat novel coronavirus in mainland China.&nbsp;

Shenzhen Kangtai Biological Products becomes the first Chinese company to enter into a deal with AstraZeneca.&nbsp;

Also read |&nbsp;<a href="https://www.wionews.com/world/oxford-astrazeneca-coronavirus-vaccine-trial-safe-produced-immune-response-data-reveals-314716">Oxford-AstraZeneca coronavirus vaccine trial: Safe &amp; produced immune response, data reveals</a> &nbsp;

AZD1222, that is jointly developed by AstraZeneca and Oxford Univesity, is one of the frontrunners in COVID-19 vaccine race.

Also read |&nbsp;<a href="https://www.wionews.com/world/brazil-signs-agreement-to-produce-astrazenecas-experimental-covid-19-vaccine-309047">Brazil signs agreement to produce AstraZeneca's experimental COVID-19 vaccine</a>

The agreement says that Shenzhen Kangtai will annually produce at least 100 million doses of AZD1222 and must be able to stretch it to 200 million doses by the end of 2021, AstraZeneca said on Thursday.&nbsp;

It also said the two pharma giants will seek the possibility of cooperation on the vaccine candidate in other markets.&nbsp;

Earlier, AstraZeneca has signed production deals with countries like the US, India, Britain, South Korea, which overall leads to the manufacturing of over two billion doses.&nbsp;

Chinese organisations have earlier tied up with other Western pharma firms such as Germany's BioNTech and US's Inovio Pharma for producing coronavirus vaccine.&nbsp;

Shenzhen Kangtai is one of China's leading vaccine makers and its shares have surged nearly 90 per cent to about $20 billion in the last one month, with its stocks witnessing a record-high on Tuesday. 
&nbsp;

AstraZeneca Plc on Thursday signed a deal with a China-based company for producing its potential drug to treat novel coronavirus in mainland China. Shenzhen Kangtai Biological Products becomes the first Chinese company to enter into a deal with AstraZeneca.

AstraZeneca Plc on Thursday signed a deal with a China-based company for producing its potential drug to treat novel coronavirus in mainland China. Shenzhen Kangtai Biological Products becomes the first Chinese company to enter into a deal with AstraZeneca. Also read | Oxford-AstraZeneca coronavirus vaccine trial: Safe & produced immune response, data reveals AZD1222, that is jointly developed by AstraZeneca and Oxford Univesity, is one of the frontrunners in COVID-19 vaccine race. Also read | Brazil signs agreement to produce AstraZeneca's experimental COVID-19 vaccine The agreement says that Shenzhen Kangtai will annually produce at least 100 million doses of AZD1222 and must be able to stretch it to 200 million doses by the end of 2021, AstraZeneca said on Thursday. It also said the two pharma giants will seek the possibility of cooperation on the vaccine candidate in other markets. Earlier, AstraZeneca has signed production deals with countries like the US, India, Britain, South Korea, which overall leads to the manufacturing of over two billion doses. Chinese organisations have earlier tied up with other Western pharma firms such as Germany's BioNTech and US's Inovio Pharma for producing coronavirus vaccine. Shenzhen Kangtai is one of China's leading vaccine makers and its shares have surged nearly 90 per cent to about $20 billion in the last one month, with its stocks witnessing a record-high on Tuesday.

AstraZeneca signs first deal with Chinese firm to produce COVID-19 vaccine

astrazeneca-vaccine

Astrazeneca Vaccine, News on Astrazeneca Vaccine, stories on Astrazeneca Vaccine, articles on Astrazeneca Vaccine, Astrazeneca Vaccine stories at Wion, Astrazeneca Vaccine news, Astrazeneca Vaccine latest news

astrazeneca vaccine

AstraZeneca conducts clinical trials of COVID-19 drug

AstraZeneca signs first deal with Chinese firm to produce COVID-19 vaccine